Showing 5,341 - 5,360 results of 7,608 for search '"oncology"', query time: 0.12s Refine Results
  1. 5341

    Cutaneous metastases of invasive lobular breast cancer as the first clinical manifestation: a case report by Saja Karaja, Ahmad Almohamed, Ayham Qatza, Ahmed Aldolly, Sanaa Mansour, Alae Aldin Almasri

    Published 2025-02-01
    “…Cutaneous metastasis (CM) is a rare phenomenon, occurring in only 0.6% to 10.4% of oncology patients. Breast carcinoma represents nearly one-third of all CM cases, although it manifests in a minority of patients with breast cancer (BC). …”
    Get full text
    Article
  2. 5342
  3. 5343
  4. 5344
  5. 5345
  6. 5346
  7. 5347
  8. 5348

    Safety of interleukin inhibitors in patients with plaque psoriasis and history of neoplasms: a multicenter retrospective study – IL PSO (Italian landscape psoriasis) by Mario Valenti, Luciano Ibba, Sara Di Giulio, Luigi Gargiulo, Piergiorgio Malagoli, Anna Balato, Carlo G. Carrera, Paolo Dapavo, Eugenia V. Di Brizzi, Valentina Dini, Francesca Gaiani, Francesco Loconsole, Angelo V. Marzano, Matteo Megna, Alessandra Michelucci, Luca Potestio, Simone Ribero, Antonio Costanzo, Alessandra Narcisi

    Published 2025-12-01
    “…However, their use in patients with a history of cancer is debated.Objective: We conducted a multicenter retrospective study across nine Italian Dermatology Units to assess the real-world effectiveness and safety of IL inhibitors (IL-23, IL-17, IL-12/23) in 136 oncological patients with moderate-to-severe plaque psoriasis. …”
    Get full text
    Article
  9. 5349
  10. 5350
  11. 5351
  12. 5352
  13. 5353
  14. 5354
  15. 5355
  16. 5356

    PD(L)1 Inhibitors Plus Lenvatinib Vs Atezolizumab Plus Bevacizumab Combined With HAIC for Unresectable HCC: A Propensity Score Matching Study by He Z, Chen H, Liang C, Tang X, Jiang L, Xie F, Liu Q, Zheng Y

    Published 2025-01-01
    “…Zhaoqian He,1– 3,* Hua Chen,1– 3,* Chen Liang,1– 3,* Xiang Tang,1– 3 Lingmin Jiang,1– 3 Feihu Xie,1– 3 Qi Liu,1– 3 Yun Zheng1– 3 1Department of Liver Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510060, People’s Republic of China; 2Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510060, People’s Republic of China; 3Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510060, People’s Republic of China*These authors contributed equally to this workCorrespondence: Yun Zheng; Qi Liu, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, 510060, People’s Republic of China, Email zhengyun@sysucc.org.cn; liuqi9@sysucc.org.cnPurpose: To compare the clinical outcomes of different systemic therapies, specifically PD(L)1 inhibitors plus Lenvatinib versus Atezolizumab plus Bevacizumab, when combined with hepatic arterial infusion chemotherapy (HAIC) based on the FOLFOX regimen (oxaliplatin, fluorouracil, and leucovorin) as first line treatment for unresectable hepatocellular carcinoma.Patients and Methods: This real-world retrospective study enrolled 294 patients with unresectable HCC. …”
    Get full text
    Article
  17. 5357
  18. 5358
  19. 5359

    A Path to High-Value Gastric Cancer Surgery Care Delivery by Swee H. Teh, MD, Sharon Shiraga, MD, Aaron M. Kellem, BS (Math), Robert A. Li, MD, David M. Le, MD, Said P. Arsalane, MSHA, Fawzi S. Khayat, MD, Yan Li, MD, I-Yeh Gong, MD, Jessica M. Lee, MD

    Published 2024-06-01
    “…This comprehensive regional program, which encompasses regionalization care, laparoscopic approach, modern oncologic care, surgical subspecialization, and the MIREC pathway, can potentially improve gastric cancer surgery outcomes. …”
    Get full text
    Article
  20. 5360